Develops gene-silencing medicines using short interfering RNA for people with rare and common diseases, including blood, cardiovascular and metabolic conditions.
10-K for FY2025, filed Mar 5, 2026We are a biotechnology company focused on discovering and developing novel molecules incorporating short interfering ribonucleic acid, or…View ↗
Divesiran (SLN124) is our potential first-in-class siRNA in Phase 2 development for polycythemia vera, or PV. PV is a rare…View ↗
Zerlasiran (SLN360) is our Phase 3 ready siRNA product candidate for cardiovascular disease that works by "silencing" the LPA gene…View ↗
SLN098 is our siRNA product candidate that works by "silencing" INHBE, a novel target for obesity supported by human genetics, strong…View ↗
Pharmaceutical collaborators pay for research and development work and related rights under collaboration agreements. The company receives fixed upfront payments and may receive milestone payments and reimbursement for staff and research costs; collaboration revenue is spread over the contract period as the work is carried out.
10-K for FY2025, filed Mar 5, 2026For all contracts the Group has concluded the license of the intellectual property and the R&D services are not distinct, as AstraZeneca…View ↗
The contracts have multiple elements of consideration (some or all of the following), namely:View ↗
Upfront payments (fixed);View ↗
Subsequent milestone payments (variable);View ↗
FTE costs rechargeable (variable);View ↗
Recharges of direct costs for certain research activities (variable).View ↗
10-K for FY2025, filed Mar 5, 2026
FY2025 revenue by product or service ↗$559K
10-K for FY2025, filed Mar 5, 2026
$559K ↗| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Royalty Income
Licensed
|
0.0%
FY2022: 3.3%
|
Royalty Income, FY2025
$0 Sources
|
Licensed |
|
Research Collaboration Income
|
100%
FY2022: 97%
|
Research Collaboration Income, FY2025
$559K Sources
|
Pharmaceutical companies buy research and development collaborations and rights related to medicines being developed from the company.
10-K for FY2025, filed Mar 5, 2026
No. It lost $88.6M in FY2025.
8-K, filed Oct 19, 2026
The transaction will be effected by means of a U.K. scheme of arrangement under Part 26 of the UK Companies Act 2006. The transaction is…View ↗
8-K, filed Aug 10, 2026
On August 10, 2026, the Company issued a press release announcing positive topline results from the Phase 2 SANRECO trial, a 36-week…View ↗
Loading...